Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2023

  1. Changes in Invasive Pneumococcal Disease in the Paediatric Population in the Second COVID-19 Pandemic Year

    Vaccines, Vol. 11, Núm. 10

  2. Multisystem inflammatory syndrome in children and SARS-CoV-2 variants: a two-year ambispective multicentric cohort study in Catalonia, Spain

    European Journal of Pediatrics, Vol. 182, Núm. 4, pp. 1897-1909

2022

  1. Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain

    Emerging Infectious Diseases, Vol. 28, Núm. 11, pp. 2321-2325

2021

  1. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 10, pp. 486-492

  2. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13

    Microbiology Spectrum, Vol. 9, Núm. 3

2020

  1. Erratum for Hernández et al., "Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Epidemic and Nonepidemic Influenza Periods"

    Journal of clinical microbiology

  2. Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2-59 months of age, Spain

    Emerging Infectious Diseases, Vol. 26, Núm. 6, pp. 1147-1155

  3. Impact of the 13-valent conjugated pneumococcal vaccine on the direct costs of invasive pneumococcal disease requiring hospital admission in children aged < 5 years: A prospective study

    Vaccines, Vol. 8, Núm. 3, pp. 1-17

  4. Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain

    PLoS ONE, Vol. 15, Núm. 2

2019

  1. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era

    Pediatric Pulmonology, Vol. 54, Núm. 5, pp. 517-524

  2. Invasive pneumococcal disease and influenza activity in a pediatric population: Impact of PCV13 vaccination in pandemic and nonpandemic influenza periods

    Journal of Clinical Microbiology, Vol. 57, Núm. 8

2017

  1. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

    PLoS ONE, Vol. 12, Núm. 8

2016

  1. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage

    Pediatric Infectious Disease Journal, Vol. 35, Núm. 4, pp. 460-463

2015

  1. Neumonía adquirida en la comunidad: tratamiento de los casos complicados y en situaciones especiales. Documento de consenso de la Sociedad Española de Infectología Pediátrica (SEIP) y Sociedad Española de Neumología Pediátrica (SENP)

    Anales de Pediatria, Vol. 83, Núm. 3, pp. 217.e1-217.e11

2013

  1. Are risk factors associated with invasive pneumococcal disease according to different serotypes?

    Human Vaccines and Immunotherapeutics

  2. Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes

    Vaccine, Vol. 31, Núm. 6, pp. 960-966

2012

  1. Clinical Presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 31, Núm. 2, pp. 124-128

  2. Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 31, Núm. 7, pp. 1487-1495

  3. Viral load at diagnosis and influenza A H1N1 (2009) disease severity in children

    Influenza and other Respiratory Viruses, Vol. 6, Núm. 6

2011

  1. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

    Vaccine, Vol. 29, Núm. 48, pp. 9020-9025